Max Healthcare, Tata Institute for Genetics and Society Sign MoU to Advance Genomics-Based Healthcare

The partnership will focus on collaborative research into rare genetic diseases, on neonatal care informed by genomic insights, and on the development of personalized medicine based on genetic profiling.

Max Healthcare and the Tata Institute for Genetics and Society (TIGS) have signed a Memorandum of Understanding (MoU) to collaborate on advancing healthcare through genomics, research, and innovation.

The agreement establishes a joint platform for research, training, and knowledge exchange in genetics and clinical science, aiming to improve patient outcomes by integrating genomics into healthcare delivery. Senior representatives from both institutions attended the signing ceremony.

Dr. Sandeep Budhiraja, Group Medical Director, Max Healthcare, said, “This partnership with the Tata Institute for Genetics and Society is a significant step forward in our commitment to bringing the latest advancements in medical sciences to our patients. By integrating genomics into our clinical practice, we can move towards a future of more personalized and effective healthcare.”

The partnership will focus on collaborative research into rare genetic diseases, on neonatal care informed by genomic insights, and on the development of personalized medicine based on genetic profiling. It will also include conferences, workshops, and training programs to encourage knowledge sharing between scientists, clinicians, and researchers.

Dr. Rakesh Mishra, Director, Tata Institute for Genetics and Society, said, “At TIGS, our mission is to use cutting-edge science to solve societal problems. This collaboration with Max Healthcare provides a unique opportunity to apply our expertise in genomics to real-world clinical challenges and ensure that our research delivers tangible benefits for patients and society.”

The collaboration will particularly strengthen research in hematology and neonatal care, with an emphasis on understanding the genetic basis of blood disorders, cancers, and critical neonatal conditions. It aims to facilitate early identification of genetic risk factors and support personalized treatment strategies, contributing to the broader adoption of genomic medicine in India.

Stay tuned for more such updates on Digital Health News